Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the
preferential rights issue totaling SEK 94.4 m has now been completed, and
provides an updated timeline for the conversion of NeuroVive’s BTUs into shares
and warrants.
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE
US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY
OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT
TO LEGAL RESTRICTIONS.

The last day of trading in BTUs will be 24 May 2016, and the first day of
trading in new shares and warrants (series 2016/2017:1 and series 2016/2017:2)
will be 26 May 2016. The conversion of BTUs in the Euroclear system will be
effected on 26 May 2016, and the new shares and warrants will appear in the
relevant VP accounts on 30 May 2016.

 After the completion of the new issue, NeuroVive’s share capital amounts to SEK
2,472,932.25. The total number of shares after registration is 49,458,645.

Advisors
Stockholm Corporate Finance AB acted as financial advisor and Advokatfirman
Lindahl KB acted as legal advisor to the company in connection with the new
issue. Aqurat Fondkommission AB acted as issuing institution in connection with
the new issue and Laika Consulting was responsible for IR and marketing.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares
are listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

 (http://www.neurovive.com/)NeuroVive Pharmaceutical AB (publ) is required to
publish the information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on the 23 May 2016, at 17.15
CET.

IMPORTANT INFORMATION
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such legal restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares or other
securities in NeuroVive.

This press release may not be published or distributed, directly or indirectly,
in or into the US, Australia, Hong Kong, Japan, Canada, New Zeeland, South
Africa or in any other jurisdiction where such distribution would be prohibited
by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 or applicable laws of
other jurisdictions.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at  www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/N
E 
VPF/quot)